Atul Dandekar
Csbo at Maze Therapeutics, Inc. (MAZE)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $5.2M
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Oct 1SEC | MAZEMaze Therapeutics, Inc. | Sell Plan | 7,50032,316 held (−19%) | $27.06 | $203K | +0.2% |
| Sep 4SEC | MAZEMaze Therapeutics, Inc. | Sell | 2,80035,950 held (−7%) | $26.38 | $74K | +2.8% |
| Sep 4SEC | MAZEMaze Therapeutics, Inc. | Sell | 39135,559 held (−1%) | $27.12 | $11K | -0.0% |
| Sep 4SEC | MAZEMaze Therapeutics, Inc. | Sell | 3,20732,352 held (−9%) | $26.01 | $83K | +4.2% |
| Sep 4SEC | MAZEMaze Therapeutics, Inc. | Sell | 3632,316 held (−0%) | $25.81 | $929 | +5.0% |
| Aug 31SEC | MAZEMaze Therapeutics, Inc. | Sell Plan | 7,50026,250 held (−22%) | $27.58 | $207K | -1.7% |
| Jul 31SEC | MAZEMaze Therapeutics, Inc. | Sell Plan | 7,10026,650 held (−21%) | $27.31 | $194K | -0.7% |
| Jul 31SEC | MAZEMaze Therapeutics, Inc. | Sell Plan | 40026,250 held (−2%) | $27.89 | $11K | -2.8% |
| Jul 1SEC | MAZEMaze Therapeutics, Inc. | Sell Plan | 7,50026,250 held (−22%) | $28.02 | $210K | -3.2% |
| Jun 2SEC | MAZEMaze Therapeutics, Inc. | Sell Plan | 7,50024,808 held (−23%) | $26.34 | $198K | +2.9% |
| May 1SEC | MAZEMaze Therapeutics, Inc. | Sell Plan | 7,50010,503 held (−42%) | $25.37 | $190K | +6.9% |
| Apr 1SEC | MAZEMaze Therapeutics, Inc. | Sell Plan | 6,71011,293 held (−37%) | $29.26 | $196K | -7.3% |
| Apr 1SEC | MAZEMaze Therapeutics, Inc. | Sell Plan | 79010,503 held (−7%) | $30.02 | $24K | -9.7% |
| Mar 3SEC | MAZEMaze Therapeutics, Inc. | Sell Plan | 3,73914,264 held (−21%) | $45.13 | $169K | -39.9% |
| Mar 3SEC | MAZEMaze Therapeutics, Inc. | Sell Plan | 3,76110,503 held (−26%) | $45.72 | $172K | -40.7% |
| Feb 2SEC | MAZEMaze Therapeutics, Inc. | Sell Plan | 1,20016,803 held (−7%) | $43.18 | $52K | -37.2% |
| Feb 2SEC | MAZEMaze Therapeutics, Inc. | Sell Plan | 3,50013,303 held (−21%) | $44.04 | $154K | -38.4% |
| Feb 2SEC | MAZEMaze Therapeutics, Inc. | Sell Plan | 2,80010,503 held (−21%) | $45.01 | $126K | -39.8% |
| Dec 31SEC | MAZEMaze Therapeutics, Inc. | Sell Plan | 66,36516,538 held (−80%) | $40.51 | $2.7M | -33.1% |
| Dec 31SEC | MAZEMaze Therapeutics, Inc. | Sell Plan | 6,03510,503 held (−36%) | $41.13 | $248K | -34.1% |
| Dec 31SEC | MAZEMaze Therapeutics, Inc. | Sell Plan | 10010,503 held (−1%) | $40.36 | $4K | -32.8% |
- Sell
Csbo Atul Dandekar sold $203K of MAZE at $27.06 — pre-scheduled 10b5-1 plan sale.
- Sell
Csbo Atul Dandekar sold $207K of MAZE at $27.58 — pre-scheduled 10b5-1 plan sale.
- Sell
Csbo Atul Dandekar sold $194K of MAZE at $27.31 — pre-scheduled 10b5-1 plan sale.
- Sell
Csbo Atul Dandekar sold $11K of MAZE at $27.89 — pre-scheduled 10b5-1 plan sale.
- Sell
Csbo Atul Dandekar sold $210K of MAZE at $28.02 — pre-scheduled 10b5-1 plan sale.
- Sell
Csbo Atul Dandekar sold $198K of MAZE at $26.34 — pre-scheduled 10b5-1 plan sale.